Abstract 1617: Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology
Samira Khalili(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Werner Rubas(University of California, San Francisco), Jonathan Zalevsky(Nektar Therapeutics (United States)), Vidula Dixit(Nektar Therapeutics (United States)), Deborah H. Charych(Lawrence Berkeley National Laboratory), Steve Doberstein(Nektar Therapeutics (United States)), Thomas K. H. Chang(University of British Columbia), Peter Kirk(Immunocore (United Kingdom)), Michael A. Eldon(Nektar Therapeutics (United States)), John L. Langowski(Novartis (Switzerland)), Aleksandrs Odinecs(Nektar Therapeutics (United States))
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403